{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:05:09Z","timestamp":1790435109093,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL62150"],"award-info":[{"award-number":["HL62150"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40268-022-00389-0","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T07:51:00Z","timestamp":1651218660000},"page":"165-173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0364-3311","authenticated-orcid":false,"given":"Theodore J.","family":"Kottom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Schaefbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhee S.","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Limper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"389_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fimmu.2018.00123","volume":"9","author":"J Tang","year":"2018","unstructured":"Tang J, Lin G, Langdon WY, Tao L, Zhang J. Regulation of C-type lectin receptor-mediated antifungal immunity. Front Immunol. 2018;9:123.","journal-title":"Front Immunol"},{"key":"389_CR2","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.3389\/fimmu.2018.01836","volume":"9","author":"RA Drummond","year":"2018","unstructured":"Drummond RA, Franco LM, Lionakis MS. Human CARD9: a critical molecule of fungal immune surveillance. Front Immunol. 2018;9:1836.","journal-title":"Front Immunol"},{"issue":"43","key":"389_CR3","doi-asserted-by":"publisher","first-page":"11392","DOI":"10.1073\/pnas.1705748114","volume":"114","author":"ES Leshchiner","year":"2017","unstructured":"Leshchiner ES, Rush JS, Durney MA, Cao Z, Dancik V, Chittick B, et al. Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatory bowel disease. Proc Natl Acad Sci USA. 2017;114(43):11392\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"389_CR4","doi-asserted-by":"publisher","first-page":"e01210","DOI":"10.1128\/AAC.01210-20","volume":"64","author":"TJ Kottom","year":"2020","unstructured":"Kottom TJ, Carmona EM, Limper AH. Targeting CARD9 with small-molecule therapeutics inhibits innate immune signaling and inflammatory response to Pneumocystis carinii beta-glucans. Antimicrob Agents Chemother. 2020;64(11):e01210-e1220.","journal-title":"Antimicrob Agents Chemother"},{"key":"389_CR5","volume-title":"Volume of distribution","author":"A Mansoor","year":"2022","unstructured":"Mansoor A, Mahabadi N. Volume of distribution. Treasure Island (FL): StatPearls; 2022."},{"issue":"7","key":"389_CR6","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1096\/fj.201701187R","volume":"32","author":"MY Jung","year":"2018","unstructured":"Jung MY, Kang JH, Hernandez DM, Yin X, Andrianifahanana M, Wang Y, et al. Fatty acid synthase is required for profibrotic TGF-beta signaling. FASEB J. 2018;32(7):3803\u201315.","journal-title":"FASEB J"},{"issue":"612","key":"389_CR7","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1126\/scisignal.aax4067","volume":"12","author":"X Yin","year":"2019","unstructured":"Yin X, Choudhury M, Kang JH, Schaefbauer KJ, Jung MY, Andrianifahanana M, et al. Hexokinase 2 couples glycolysis with the profibrotic actions of TGF-beta. Sci Signal. 2019;12(612):4067.","journal-title":"Sci Signal."},{"issue":"7","key":"389_CR8","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.4049\/jimmunol.164.7.3755","volume":"164","author":"R Vassallo","year":"2000","unstructured":"Vassallo R, Standing JE, Limper AH. Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol. 2000;164(7):3755\u201363.","journal-title":"J Immunol"},{"issue":"2","key":"389_CR9","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1096\/fj.201902354R","volume":"34","author":"JH Kang","year":"2020","unstructured":"Kang JH, Jung MY, Choudhury M, Leof EB. Transforming growth factor beta induces fibroblasts to express and release the immunomodulatory protein PD-L1 into extracellular vesicles. FASEB J. 2020;34(2):2213\u201326.","journal-title":"FASEB J"},{"issue":"4","key":"389_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrmicro1621","volume":"5","author":"CF Thomas Jr","year":"2007","unstructured":"Thomas CF Jr, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol. 2007;5(4):298\u2013308.","journal-title":"Nat Rev Microbiol"},{"issue":"10","key":"389_CR11","doi-asserted-by":"publisher","first-page":"e00396","DOI":"10.1128\/IAI.00396-17","volume":"85","author":"HM Evans","year":"2017","unstructured":"Evans HM, Simpson A, Shen S, Stromberg AJ, Pickett CL, Garvy BA. The trophic life cycle stage of the opportunistic fungal pathogen Pneumocystis murina hinders the ability of dendritic cells to stimulate CD4(+) T cell responses. Infect Immun. 2017;85(10):e00396-e417.","journal-title":"Infect Immun"},{"issue":"5","key":"389_CR12","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/infdis\/jiw249","volume":"214","author":"G Kutty","year":"2016","unstructured":"Kutty G, Davis AS, Ferreyra GA, Qiu J, Huang DW, Sassi M, et al. \u03b2-glucans are masked but contribute to pulmonary inflammation during pneumocystis pneumonia. J Infect Dis. 2016;214(5):782\u201391.","journal-title":"J Infect Dis"},{"issue":"3","key":"389_CR13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1128\/IAI.01181-12","volume":"81","author":"MJ Linke","year":"2013","unstructured":"Linke MJ, Ashbaugh A, Collins MS, Lynch K, Cushion MT. Characterization of a distinct host response profile to Pneumocystis murina asci during clearance of pneumocystis pneumonia. Infect Immun. 2013;81(3):984\u201395.","journal-title":"Infect Immun"},{"issue":"21","key":"389_CR14","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJM199011223232104","volume":"323","author":"SA Bozzette","year":"1990","unstructured":"Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome California Collaborative Treatment Group. N Engl J Med. 1990;323(21):1451\u20137.","journal-title":"N Engl J Med"},{"issue":"12","key":"389_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/14656566.2021.1915989","volume":"22","author":"RB Weyant","year":"2021","unstructured":"Weyant RB, Kabbani D, Doucette K, Lau C, Cervera C. Pneumocystis jirovecii: a review with a focus on prevention and treatment. Expert Opin Pharmacother. 2021;22(12):179\u20131592.","journal-title":"Expert Opin Pharmacother"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-022-00389-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-022-00389-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-022-00389-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T02:23:18Z","timestamp":1654309398000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-022-00389-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1007\/s40268-022-00389-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.19.469250","asserted-by":"object"}]},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"assertion":[{"value":"1 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Mayo Foundation, the Walter and Leonore Annenberg Foundation, and NIH grant R01-HL62150 to AHL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Theodore J. Kottom, Kyle Schaefbauer, Eva M. Carmona, Eunhee S. Yi, and Andrew H. Limper declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Mayo Clinic IACUC (approved protocol A00005722-20).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TJK, KS, ESY, and AHL made substantial contributions to the conception or design of the work, and the acquisition, analysis, or interpretation of data. EMC revised the manuscript critically for important intellectual content and all authors approved the version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}